Recruiting

3

35

RoW

Mirvetuximab Soravtansine, IMGN853, MIRV

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer

04/23

12/23

Not yet recruiting

3

110

NA

Mirvetuximab Soravtansine, MIRV, IMGN853

AbbVie

Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, Fallopian Tube Cancers, High Folate Receptor-Alpha Expression, Platinum Resistant

03/28

03/28

Not yet recruiting

2

136

Europe

Mirvetuximab Soravtansine, Powder and solvent for concentrate for solution for infusion, Solution for infusion, Capsule, hard, Film-coated tablet, , Caelyx, Carboplatin Kabi, Paclitaxel-GRY®, Gemedac®, Zejula, Lynparza, Rubraca

AGO Research GmbH, ImmunoGen, Inc.

This trial evaluates the efficacy and safety of Mirvetuximab soravtansine (IMGN853) plus Carboplatin chemotherapy in FRα high patients with recurrent ovarian cancer who are eligible for platinum-based chemotherapy., Safety and efficacy for carboplatin with Mirvetuximab soravtansine (IMGN853) compared to carboplatin combination chemotherapy, Diseases [C] - Cancer [C04]

 

 

Active, not recruiting

2

18

US

Pembrolizumab, Keytruda, IMGN853, Mirvetuximab soravtansine, Elahere

Dana-Farber Cancer Institute, ImmunoGen, Inc., Merck Sharp & Dohme LLC

Endometrial Cancer

06/24

05/27

Active, not recruiting

2

136

Europe

Carboplatin, Pegylated liposomal doxorubicin (PLD), Gemcitabine, Paclitaxel, Mirvetuximab Soravtansine

AGO Research GmbH, ImmunoGen, Inc.

Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma

12/25

12/26

Active, not recruiting

2

125

Europe, Canada, US, RoW

Mirvetuximab soravtansine, MIRV, IGN853, Carboplatin

AbbVie

High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer

05/26

05/26

Not yet recruiting

2

140

NA

Carboplatin, Mirvetuximab Soravtansine, MIRV, IMGN853, ELAHERE™

AbbVie

Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Neoadjuvant

10/29

10/29

Recruiting

2

70

US

mirvetuximab soravtansine (MIRV; IMGN853)

University of Alabama at Birmingham

Ovarian Cancer, Fallopian Tube, Primary Peritoneal Cancer

05/26

05/28

Completed

1

25

US

Laboratory Biomarker Analysis, Mirvetuximab Soravtansine, IMGN853, M9346A-sulfo-SPDB-DM4, Pharmacokinetic Study, PHARMACOKINETIC, PK Study, Rucaparib Camsylate, 8-Fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one ((1S,4R)-7,7dimethyl-2-oxobicyclo[2.2.1]hept-1-yl)methanesulfonic Acid Salt, C0-338, Rubraca, Rucaparib Phosphate

Ohio State University Comprehensive Cancer Center, ImmunoGen, Inc., Clovis Oncology, Inc.

BRCA1 Gene Mutation, BRCA2 Gene Mutation, Folate Receptor Alpha Positive, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Uterine Corpus Carcinoma, Recurrent Uterine Serous Carcinoma, Recurrent Uterine Carcinosarcoma, Platinum Resistant Ovarian Cancer

06/22

12/22

Completed

1

86

Europe, Canada, US

Pegylated Liposomal Doxorubicin + SL-172154, Doxil, PLD, Caelyx, Mirvetuximab + SL-172154, IMGN853, MIRV

Shattuck Labs, Inc.

Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer, Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Primary Peritoneal Carcinoma

02/25

02/25

Active, not recruiting

3

48

Japan

CC-93538, Cendakimab, BMS-986355, Placebo

Celgene

Eosinophilic Gastroenteritis

07/24

Active, not recruiting

3

259

Europe, Canada, Japan, US, RoW

CC-93538, BMS-986355, cendakimab

Celgene

Eosinophilic Esophagitis

06/26

09/26

Receptos

 

 

Completed

1

25

RoW

Cendakimab, CC-93538, BMS-986355, RPC4046, Placebo

Bristol-Myers Squibb

Healthy Participants

06/23

06/23

Not yet recruiting

4

50

Europe

VIEKIRAX, EXVIERA, 043841, Film-coated tablet, VIEKIRAX - 12,5MG/75MG/50MG COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PVC/PE/PCTFE/ALU) - 56 COMPRESSE (CONFEZIONE MULTIPLA), EXVIERA - 250 MG COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PVC/PE/PCTFE/ALU) - 56 COMPRESSE (CONFEZIONE MULTIPLA)

DIPARTIMENTO AD ATTIVITà INTEGRATA CHIRURGICO, MEDICO, ODONTOIATRICO E DI SCIENZE MORFOLOGICHE, ABBVIE SRL

Genotype 1 and 4 Chronic Hepatitis C Virus (HCV) Infection Epatite cronica HCV-positiva, genotipo 1 e 4, Hepatitis C EPATITE C, Diseases [C] - Virus Diseases [C02]

 

 

Ongoing

3

1

Europe

ABT-450/r/ABT-267; ABT333

Egyesített Szent István és Szent László Kórház - Rendelőintézet

 

 

Ongoing

3

1

Europe

ABT-450/ritonavir/ABT-267, ABT-333,

Semmelweis Egyetem Transzplantációs és Sebészeti Klinika

 

 

Recruiting

N/A

300

RoW

Direct-acting antiviral agents, daclatasvir, asunaprevir, ombitasvir, paritaprevir, dasabuvir, sofosbuvir, velpatasvir, ledipasvir, elbasvir, grazoprevir, danoprevir, glecaprevir, pibrentasvir, voxilaprevir

Qing XIe, Gilead Sciences, Tigermed Consulting Co., Ltd

Hepatitis C, Chronic

07/21

08/21

Completed

4

75

RoW

Ibrutinib 420 mg, Imbruvica, Ibrutinib 560 mg

Johnson & Johnson Private Limited

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

05/23

05/23

Completed

4

17

RoW

Ibrutinib, JNJ-54179060, PCI-32765

Janssen Research & Development, LLC

Waldenstrom Macroglobulinemia

03/24

03/24

Enrolling by invitation

4

600

Europe, Canada, US, RoW

Ibrutinib

Pharmacyclics Switzerland GmbH, Janssen Biotech, Inc., including Johnson & Johnson

Lymphoma, B-Cell, Lymphoma, Non-Hodgkin, Leukemia, B-cell, Graft Vs Host Disease, Solid Tumor

05/27

05/27

Active, not recruiting

3

547

Canada, US

Bendamustine Hydrochloride, Belrapzo, Bendamustin Hydrochloride, Bendeka, CEP 18083, CEP-18083, CEP18083, Cytostasan Hydrochloride, Levact, Ribomustin, SyB L-0501, Treakisym, Treanda, VIVIMUSTA, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Ibrutinib, BTK Inhibitor PCI-32765, CRA 032765, CRA-032765, CRA032765, Imbruvica, PCI 32765, PCI-32765, PCI32765, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Quality of Life Assessment, Rituximab, ABP 798, ABP-798, ABP798, BI 695500, BI-695500, BI695500, Blitzima, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT P10, CT-P10, CTP10, GP 2013, GP-2013, GP2013, IDEC 102, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, IDEC102, Ikgdar, Mabtas, MabThera, Monoclonal Antibody IDEC-C2B8, PF 05280586, PF-05280586, PF05280586, Riabni, Ritemvia, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar GP2013, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, Rituximab-abbs, Rituximab-arrx, Rituximab-blit, Rituximab-pvvr, Rituximab-rite, Rituximab-rixa, Rituximab-rixi, Rixathon, Riximyo, RTXM 83, RTXM-83, RTXM83, Ruxience, Truxima

National Cancer Institute (NCI)

Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia

08/18

Active, not recruiting

3

55

Canada

Canadian Cancer Trials Group

Chronic Lymphocytic Leukemia

04/19

01/26

Active, not recruiting

3

533

Europe, US, RoW

Acalabrutinib, ACP-196, Ibrutinib

Acerta Pharma BV

Chronic Lymphocytic Leukemia

09/20

01/28

Recruiting

3

870

Europe

R-CHOP/R-DHAP, rituximab, CHOP, DHAP, Ibrutinib (Induction), Imbruvica, ASCT conditioning, THAM or BEAM, Ibrutinib (Maintenance)

Prof. Dr. M. Dreyling (co-chairman), LMU Klinikum

Mantle Cell Lymphoma

05/21

05/26

Not yet recruiting

3

500

Europe, RoW

pirtobrutinib, Ibrutinib, [na], [LOXO-305], Film-coated tablet, Tablet, IMBRUVICA

Loxo Oncology, Inc., a wholly owned subsidiary of Eli Lilly and Company, LOXO ONCOLOGY INCORPORATED, Loxo Oncology, Inc., a wholly owned subsidiary of Eli Lilly and Company, Loxo Oncology Inc

Mantle cell lymphoma, a cancer of white blood cells (developing in a certain part of the lymph node), which help the body fight infections, Diseases [C] - Cancer [C04]

 

 

Ongoing

3

650

Europe

Pirtobrutinib, Ibrutinib, LOXO-305, Tablet, Capsule, hard, IMBRUVICA

Loxo Oncology, Inc., Loxo Oncology, Inc.

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma krónikus limfocitás leukémia / kis limfocitás limfóma, Chronic lymphocytic leukaemia/Small Lymphocytic Lymphoma is a type of cancer that affects the white blood cells and tends to progress slowly over many years, Diseases [C] - Cancer [C04]

 

 

Ongoing

3

365

Europe

Zilovertamab, Ibrutinib, Zilovertamab, PCI-32765, Solution for infusion, Capsule, hard

Oncternal Therapeutics, Inc, Oncternal Therapeutics, Inc

Relapsed or Refractory Mantle Cell Lymphoma Linfoma de células del manto recidivante o resistente, Mantle Cell Lymphoma Linfoma de células del manto, Diseases [C] - Cancer [C04]

 

 

Recruiting

3

1200

Europe, Canada, Japan, US, RoW

Nemtabrutinib, MK-1026, ARQ 531, Ibrutinib, Acalabrutinib

Merck Sharp & Dohme LLC

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

09/32

09/32

Active, not recruiting

3

92

US, RoW

Autologous Bone Marrow Transplantation, ABMT, Autologous Blood and Marrow Transplantation, Autologous Bone Marrow Transplant, Autologous Marrow Transplantation, Autologous Hematopoietic Stem Cell Transplantation, AHSCT, Autologous, Autologous Hematopoietic Cell Transplantation, Autologous Stem Cell Transplant, Autologous Stem Cell Transplantation, Stem Cell Transplantation, Autologous, Carmustine, BCNU, Becenum, Becenun, BiCNU, Bis(chloroethyl) Nitrosourea, Bis-Chloronitrosourea, Carmubris, Carmustin, Carmustinum, FDA 0345, N,N'-Bis(2-chloroethyl)-N-nitrosourea, Nitrourean, Nitrumon, NSC 409962, NSC409962, SK 27702, SRI 1720, WR 139021, WR-139021, WR139021, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B 518, B-518, B518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR 138719, WR- 138719, WR-138719, WR138719, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP 16213, VP-16, VP-16-213, VP-16213, VP16, VP16213, Ibrutinib, BTK Inhibitor PCI-32765, CRA 032765, CRA-032765, CRA032765, Imbruvica, PCI 32765, PCI-32765, PCI32765, Laboratory Biomarker Analysis, Melphalan, Alanine Nitrogen Mustard, CB-3025, L-PAM, L-Phenylalanine Mustard, L-Sarcolysin, L-Sarcolysin Phenylalanine mustard, L-Sarcolysine, Melphalan for Injection-Hepatic Delivery System, Melphalanum, Phenylalanine Mustard, Phenylalanine Nitrogen Mustard, Sarcoclorin, Sarkolysin, WR-19813, Pharmacogenomic Study, PHARMACOGENOMIC, Placebo Administration

National Cancer Institute (NCI)

Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type

06/24

12/25

Completed

3

352

Europe, Canada, US, RoW

Ibrutinib, Venetoclax, Placebo Oral tablet to match Venetoclax

Pharmacyclics LLC., Janssen Research & Development, LLC

Mantle-Cell Lymphoma

06/24

06/24

3

300

Europe, RoW

INCA034176, Axatilimab, Best Available Therapy (BAT), BAT could include:, • Calcineurin inhibitor (cyclosporine or tacrolimus), • Extracorporeal photopheresis (ECP), • Mycophenolate mofetil (MMF), • A mammalian target of rapamycin (mTOR) inhibitor (everolimus or sirolimus), • Rituximab, • Pentostatin, • Proteasome inhibitors, • Imatinib, • Ibrutinib

Incyte Corporation

Chronic Graft-versus-host-disease

05/28

11/32

Withdrawn

3

365

NA

Zilovertamab, Cirmtuzumab, UC961, Ibrutinib, Imbruvica, Placebo

Oncternal Therapeutics, Inc, Pharmacyclics LLC.

Lymphoma, Mantle-Cell, Lymphoma, Lymphoproliferative Disorders, Lymphatic Diseases, Immunoproliferative Disorders, Immune System Diseases, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

11/26

12/26

Active, not recruiting

3

897

Europe, RoW

Ibrutinib, Imbruvica, Venetoclax, ABT-199, Venclyxto, Obinutuzumab, GA101, Gazyvaro

German CLL Study Group, Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Nordic CLL Study Group (NCLLSG), Swiss Group for Clinical Cancer Research (SAKK), Cancer Trials Ireland, Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA), Grupo Español de Leucemia Linfocítica Crónica (GELLC), The Israeli CLL Study Group (ICLLSG), Janssen Pharmaceutica N.V., Belgium, AbbVie, Hoffmann-La Roche

Chronic Lymphoid Leukemia

09/27

09/27

Active, not recruiting

3

650

Europe, Canada, Japan, US, RoW

Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib

Loxo Oncology, Inc., Eli Lilly and Company

Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma

06/25

01/28

Ongoing

2/3

400

Europe

Ibrutinib, Rituximab, Bendamustine hydrochloride, Cyclophosphamide, Doxorubicin hydrochloride, Vincristine sulphate, Prednisolone, Capsule, hard, Concentrate for solution for injection/infusion, Lyophilisate for solution for infusion, Powder for solution for infusion, Solution for infusion, Solution for injection, Tablet, Ibrutinib, doxorubicin

Plymouth Hospitals NHS Trust, Cancer Research UK, Janssen Pharmaceutica NV

Untreated symptomatic Mantle Cell Lymphoma, Untreated symptomatic Mantle Cell Lymphoma, Diseases [C] - Cancer [C04]

 

 

Enrolling by invitation

2/3

122

RoW

Ibrutinib

Nanfang Hospital of Southern Medical University

FLT3-ITD Mutation, Acute Myeloid Leukemia, Brutons Tyrosine Kinase

08/22

09/23

Recruiting

2/3

148

Europe

Dexamethasone, cyclophosphamide, rituximab, Rituximab, ibrutinib

University College, London, Janssen-Cilag Ltd.

Waldenstrom Macroglobulinemia

03/30

03/30

Active, not recruiting

2

86

US

PCI 32765

National Heart, Lung, and Blood Institute (NHLBI)

Leukemia, Leukemia, Lymphocytyc, CLL (Chronic Lymphocytic Leukemia), SLL (Small Lymphocytic Lymphoma)

06/14

09/34

Ongoing

2

170

Europe

Decitabine, ibrutinib, Powder for concentrate for solution for infusion, Capsule, soft, Dacogen, Imbruvica

HOVON Foundation, Dutch Cancer Society, Janssen-Cilag International NV

Acute Meyloid Leukemia and High Risk Myelodysplastic syndromes, Acute Meyloid Leukemia and High Risk Myelodysplastic syndromes, Diseases [C] - Cancer [C04]

 

 

Ongoing

2

17

Europe

Ibrutinib, JNJ-54179060, Capsule, Ibrutinib

The Royal Marsden NHS Foundation Trust

Her2 or cMYC positive advanced oesophagogastric carcinomas, Cancers arising from either the oesophagus or stomach that display abnormalities of 2 specific genes which are implicated in cancer development: either the Her2 gene, the cMYC gene or both., Diseases [C] - Cancer [C04]

 

 

Active, not recruiting

2

154

US

ibrutinib, Bruton's tyrosine kinase inhibitor PCI-32765, BTK inhibitor PCI-32765, PCI-32765, Correlative laboratory samples, laboratory biomarker anyalysis, quality of life assessment

Kami Maddocks, MD

Prolymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory/Relapsed Chronic Lymphocytic Leukemia

07/16

06/25

Active, not recruiting

2

41

US, Canada, RoW

Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Laboratory Biomarker Analysis

Mayo Clinic, National Cancer Institute (NCI)

Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Refractory Follicular Lymphoma

10/16

 

Ongoing

2

31

Europe

VENETOCLAX, [ABT-199], Film-coated tablet

OSPEDALE SAN RAFFAELE, Abbvie

Relapsed or Refractory Chronic Lymphocytic Leukemia Leucemia Linfatica Cronica Recidivante o Refrattaria, Chronic Lymphocytic Leukemia relapsed or refractory to previous treatments Leucemia Linfatica Cronica ricaduta o non responsiva ai trattamenti precedenti, Diseases [C] - Blood and lymphatic diseases [C15]

 

 

Active, not recruiting

2

18

US

Ibrutinib, BTK Inhibitor PCI-32765, CRA 032765, CRA-032765, CRA032765, Imbruvica, PCI 32765, PCI-32765, PCI32765, Laboratory Biomarker Analysis, Pharmacogenomic Study, PHARMACOGENOMIC, Pharmacological Study

National Cancer Institute (NCI)

Metastatic Melanoma, Recurrent Cutaneous Melanoma, Stage IV Cutaneous Melanoma AJCC v6 and v7

02/18

03/26

Not yet recruiting

2

40

Europe

Capsule, hard, IMBRUVICA 140 mg hard capsules

Universitätsklinikum Münster, Janssen-Cilag GmbH

diffuse large B-cell lymphoma diffuses großzelliges B-Zell-Lymphom, malignant disease of the lymphatic system bösartige Erkrankung des lymphatischen Systems, Diseases [C] - Blood and lymphatic diseases [C15]

 

 

Active, not recruiting

2

84

Europe

Ibrutinib 140 MG Oral Capsule [Imbruvica], Ofatumumab

PETHEMA Foundation

Chronic Lymphocytic Leukemia

07/18

09/22

Not yet recruiting

2

90

Europe

Ibrutinib, IMP1, Capsule, hard, IMBRUVICA - 140 MG -CAPSULE RIGIDE -USO ORALE - FLACONE (HDPE) - 1 FLACONE (120 CAPSULE RIGIDE)

FONDAZIONE ITALIANA LINFOMI ONLUS, Janssen-Cilag S.p.A

Activated-B-Cell Lymphoma (ABC)-DLBCLat intermediate-high and high risk (IPI =2) Linfoma diffuso a grandi cellule B con profilo ABC (Activated-B-Cell) e rischio intermedio/alto o alto (IPI = 2), B-Cell Lymphoma (ABC)-DLBCLat intermediate-high and high risk Linfoma diffuso a grandi cellule B con profilo ABC e rischio intermedio/alto o alto, Diseases [C] - Blood and lymphatic diseases [C15]

 

 

Active, not recruiting

2

50

Europe

IBRUTINIB, Imbruvica, Rituximab

Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea, Janssen-Cilag, S.A.

Mantle Cell Lymphoma

12/19

12/24

Not yet recruiting

2

36

Europe

Capsule, hard, Imbruvica

University of Cologne, JANSSEN-CILAG GmbH

relapsed lymphocyte-predominant Hodgkin lymphoma rezidiviertes nodulär Lymphozyten-prädominantes Hodgkin Lymphom, relapsed Hodgkin lymphoma (cancer of lymphatic system) Rückfall eines Hodgkin Lymphoms (Krebserkrankung des lymphatischen Systems), Diseases [C] - Cancer [C04]